Register Login

Passage Bio Inc (PASG)

  • Event
  • May 18, 2022, 11:16 UTC

(10% Negative) PASSAGE BIO, INC. (PASG) Announces Delay in offers Trials for Washington Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 8:54 p.m.

    📋 PASSAGE BIO, INC. (PASG) - Clinical Trial Update

    Filing Date: 2022-05-18

    Accepted: 2022-05-18 07:16:42

    Event Type: Clinical Trial Update

    Event Details:

    Passage Bio Inc (PASG) Announces Clinical Trial Update Passage Bio Inc (PASG) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: offers, held
    • Diseases/Conditions: Washington, 2H22​PHILADELPHIA
    • Clinical Stage: clinical trial, Phase 1
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process
    • Collaboration: Passage Bio, Inc.
      • expected in 2H22​PHILADELPHIA, May 18, 2022
      • expected in the second half of 2022

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Passage Bio Inc
    • CIK: 0001787297
    • Ticker Symbol: PASG
    • Period End Date: 2022-05-18
    • Document Type: 8-K

Search

News categories